News
UK drug companies must disclose funding of patients' groups
BMJ 2006; 332 doi: https://doi.org/10.1136/bmj.332.7533.69-a (Published 12 January 2006) Cite this as: BMJ 2006;332:69- Michael Day
- London
Drug companies must make public their involvement with patients' advocacy groups, under a revised industry code of practice introduced in the United Kingdom this month.
From 1 January firms are expected to name all patients' organisations that receive their financial support. They must also set out details of such relationships and any funding provided, say the new rules of the Association of the British Pharmaceutical Industry. The update …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.